Attovia Therapeutics
ATTO
Attovia Therapeutics (ATTO) analyst forecast and price target
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Morgan Stanley | Initiated Coverage | Overweight | $39.00 | Aug 31, 2026 |
| RBC Capital | Initiated Coverage | Outperform | $45.00 | Aug 31, 2026 |
| Leerink Partners | Initiated Coverage | Outperform | $52.00 | Aug 31, 2026 |
| LifeSci Capital | Initiated Coverage | Outperform | $45.00 | Aug 31, 2026 |
| Citigroup | Initiated Coverage | Buy | $30.00 | Aug 31, 2026 |
Frequently asked questions
What is the latest analyst rating on ATTO?
On Aug 31, 2026, Morgan Stanley initiated coverage of Attovia Therapeutics at Overweight with a price target of $39.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.